- Home
- OCG vs NTHI Comparison
OCG vs NTHI Comparison
Compare OCG & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCG | NTHI |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.1M | 193.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OCG | NTHI |
|---|---|---|
| Price | $1.87 | $9.13 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 51.3K |
| Earning Date | 11-14-2025 | 02-19-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $316,807.00 | $59,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.58 | $3.20 |
| 52 Week High | $4,243.76 | $25.00 |
Technical Indicators
Market Signals| Indicator | OCG | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 60.64 | 50.58 |
| Support Level | $1.63 | $7.99 |
| Resistance Level | $2.53 | $10.19 |
| Average True Range (ATR) | 0.20 | 0.79 |
| MACD | 0.31 | -0.04 |
| Stochastic Oscillator | 74.22 | 33.82 |
Price Performance
Historical ComparisonAbout OCG Oriental Culture Holding LTD
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).